Skip to main content
    I

    Inovio Pharmaceuticals Inc (INO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.63
    +0.23 (+16.43%)

    Market Cap: $262.23M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Inovio Pharmaceuticals Inc (INO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Inovio Pharmaceuticals (INO) has a market cap of $262.23M and an enterprise value of $215.27M. It kept -30457.17% of revenue as net income over the last 12 months. Its share count is up 89.07% from a year earlier.

    Total Valuation

    Enterprise value is 17.91% below the market cap, as cash exceeds debt.

    Market Cap$262.23M
    Enterprise Value$215.27M
    Latest price (Nov 17, 2026)$1.63

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 20.85% in the quarter ended Sep 30, 2026 and grew 87.22% a year over 2 years.

    Shares Outstanding98.63M
    Shares Change (YoY)+89.07%
    Shares Change (QoQ)+20.85%
    Share Count Growth (2Y CAGR)+87.22%

    Valuation Ratios

    The price to sales ratio is 537.9x. Its year-end P/S ranged from 9.2x to 415.3x from 2016 to 2024.

    P/S Ratio537.9x
    Forward P/S700.2x

    Price Statistics

    The stock is down 20.49% over 52 weeks and trades 36.97% above its 50-day average.

    Beta (1Y)0.56
    52-Week Change-20.49%
    1-Month Change+63.00%
    3-Month Change+25.38%
    6-Month Change+33.61%
    5-Year Change-99.30%
    10-Year Change-99.22%
    Total Return (1Y)-20.49%
    Total Return (3Y CAGR)-31.84%
    Total Return (5Y CAGR)-54.82%
    Return vs SPY (1Y)-25.32%
    Max Drawdown (1Y)-76.83%
    Max Drawdown (3Y)-95.66%
    Sharpe Ratio (1Y)-0.09
    Correlation with SPY (1Y)0.05
    50-Day Average$1.19
    200-Day Average$1.26
    52-Week Range$0.56 to $2.72
    RSI (14 Days)60.0
    Average Volume (20 Days)27.74M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.57x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio0.57x
    Quick Ratio0.57x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on Assets (ROA)-118.29%
    ROA (5Y Average)-85.92%
    Asset Turnover0.00x

    Scores

    INO has an Altman Z-Score of -47.32, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.

    Altman Z-Score-47.32
    Altman Z ZoneDistress
    Piotroski F-Score0 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $233.56K over the last 12 months is up 28.09% from the 12 months before.

    Revenue$233.56K
    Revenue Growth (YoY)+28.09%
    Gross Profit-$455.15K
    Operating Income-$77.58M
    Pretax Income-$65.91M
    Net Income-$71.14M
    EBITDA-$62.36M
    EBIT-$65.33M
    Reported EPS (TTM)-$0.89

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$46.96M
    Total Debt$0
    Net Cash$46.96M
    Net Cash Per Share$0.48
    Working Capital-$38.03M
    Shareholder Equity-$33.92M
    Total Assets$60.14M
    Total Liabilities$94.06M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$74.28M
    FCF Per Share-$0.68
    Depreciation and Amortization$2.98M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -33214.90%.

    Gross Margin-194.88%
    Operating Margin-33214.90%
    Pretax Margin-28219.46%
    Net Margin-30457.17%
    EBITDA Margin-26699.53%
    EBIT Margin-27973.61%

    Growth

    Revenue fell 81.47% a year over 3 years.

    Revenue Growth (3Y CAGR)-81.47%
    Revenue Growth (5Y CAGR)-61.18%
    Book Value Per Share Growth (2Y CAGR)-90.01%
    Tangible Book Per Share Growth (2Y CAGR)-90.01%

    Revenue and profit by year

    Dividends and Yields

    INO does not pay a dividend.

    Buyback Yield-42.24%
    Shareholder Yield-42.24%

    Stock Splits

    The last split was a 1-for-12 reverse split on Jan 25, 2024.

    Last Split DateJan 25, 2024
    Split TypeReverse split
    Split Ratio1:12

    Peer Position

    Against 5 similar companies, INO has the highest P/S.

    P/S Ratio537.9x vs 4.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)+28.09% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 3051.14% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+3051.14%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About INO

    What is INO's market cap?

    Inovio Pharmaceuticals has a market cap of $262.23M. Its enterprise value, which adds debt and subtracts cash, is $215.27M.

    How many shares of INO are outstanding?

    Inovio Pharmaceuticals has 98.63M shares outstanding. The count is up 89.07% from a year earlier.

    Does INO pay a dividend?

    No. Inovio Pharmaceuticals does not pay a dividend.

    How much debt does INO have?

    Inovio Pharmaceuticals has $0 of total debt and $46.96M of cash and equivalents, a net cash position of $46.96M.